MAP2K7 and melanoma: To test the sensitivity of melanoma cells to the MEK inhibitor trametinib, viability assays were performed using different melanoma cell lines (SKMEL23, SKMEL113 and WM1366) and PDSCs (TÜMEL62.1, TÜMEL110, TÜMEL119, TÜMEL123-1, TÜMEL173 and TÜMEL176).